Metforal (Metformin Hydrochloride)

Metforal is a Biguanide that acts on glucose metabolism to manage hyperglycaemia.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
• Prediabetes (impaired glucose tolerance): delays progression to overt diabetes.
• Polycystic ovary syndrome: improves insulin resistance and may restore ovulatory function.

• Metformin Hydrochloride reduces hepatic gluconeogenesis, decreases intestinal glucose absorption, and enhances peripheral insulin sensitivity by activating AMP‑activated protein kinase (AMPK). This combined action results in lower circulating glucose without directly stimulating insulin secretion.

Metforal may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects

• Nausea: transient discomfort often occurring after the first dose.
• Diarrhoea: watery stools that usually improve with continued therapy.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: brief alteration of taste perception.
• Loss of appetite: reduced desire to eat.
• Flatulence: increased intestinal gas.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening metabolic disturbance.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Vitamin B12 deficiency: may develop with long‑term use.
• Hepatic failure: rare hepatic injury.
• Hypoglycaemia: uncommon when used alone but possible with other agents.
• Acute pancreatitis: very rare inflammatory condition of the pancreas.

Before initiating Metforal, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

• Renal function: assess eGFR and avoid use if severely impaired.
• Hepatic function: monitor liver enzymes in patients with liver disease.
• Vitamin B12 status: consider periodic testing during long‑term therapy.
• Elderly patients: start at lower doses and monitor for accumulation.
• Heart failure: use with caution in unstable or severe cases.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Metforal can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: increase risk of lactic acidosis.
• Cimetidine: may raise metformin plasma concentrations.
• Alcohol: potentiates lactic acidosis risk.
• Didanosine (or other nucleoside reverse transcriptase inhibitors): heightened risk of lactic acidosis.
• Loop diuretics: may impair renal clearance of metformin.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• ACE inhibitors or ARBs: monitor renal function and potassium.
• Thiazide diuretics: can affect glucose control.
• Corticosteroids: may increase blood glucose, requiring dose adjustment.
• Oral contraceptives: may slightly raise metformin levels.
• Digoxin: monitor for potential increased serum concentrations.